RARE
HEALTHCAREUltragenyx Pharmaceutical Inc
$25.93+0.92 (+3.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RARE Today?
No stock-specific AI insight has been generated for RARE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.29$42.37
$25.93
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-5.83
Dividend Yield—
Dividend / Share—
ROE-6.1%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume3.5M
Avg Volume (10D)—
Shares Outstanding98.5M
RARE News
34 articles- Ultragenyx to Participate at Bank of America’s 2026 Healthcare ConferenceYahoo Finance·May 6, 2026
- RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectYahoo Finance·May 6, 2026
- Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Ultragenyx Pharmaceutical Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Ultragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·May 5, 2026
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowYahoo Finance·Apr 29, 2026
- Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman TrialYahoo Finance·Apr 29, 2026
- Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate UpdateYahoo Finance·Apr 29, 2026
- Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·Apr 28, 2026
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 24, 2026
- FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111Yahoo Finance·Apr 19, 2026
- Tactical Resources Secures 1.5M Tons of Crushed Aggregate Feedstock in TexasYahoo Finance·Apr 15, 2026
- Is Ultragenyx Pharmaceutical (RARE) Pricing Reflect Its Long Term Potential After 5 Year SlumpYahoo Finance·Apr 10, 2026
- Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·Apr 8, 2026
- RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo SyndromeYahoo Finance·Apr 6, 2026
- ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the FirmGlobeNewswire Inc.·Apr 6, 2026
- TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPCGlobeNewswire Inc.·Apr 5, 2026
- RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RAREGlobeNewswire Inc.·Apr 5, 2026
- Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)Yahoo Finance·Apr 2, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 1, 2026
- Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 StudyYahoo Finance·Apr 1, 2026
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Apr 1, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREOGlobeNewswire Inc.·Mar 31, 2026
- Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 INDYahoo Finance·Mar 31, 2026
- Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. InvestorsGlobeNewswire Inc.·Mar 31, 2026
- POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - POMGlobeNewswire Inc.·Mar 30, 2026
- RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RAREGlobeNewswire Inc.·Mar 30, 2026
- INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD LawGlobeNewswire Inc.·Mar 29, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 29, 2026
- Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RAREGlobeNewswire Inc.·Mar 26, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 25, 2026
- Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineGlobeNewswire Inc.·Mar 25, 2026
All 34 articles loaded
Price Data
Open$25.91
Previous Close$25.01
Day High$27.27
Day Low$24.23
52 Week High$42.37
52 Week Low$18.29
52-Week Range
$18.29$42.37
$25.93
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-5.83
Dividend Yield—
Dividend / Share—
ROE-6.1%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume3.5M
Avg Volume (10D)—
Shares Outstanding98.5M
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—